The mission is to deliver highly effective, off-the-shelf, allogeneic, natural killer (NK) cell-based therapies that are safe and accessible to cancer patients. Our established manufacturing-first approach has enabled us to produce, store and ship our product candidates and make them accessible like traditional protein biologic therapies. Our lead product candidate, AB-101, is an off-the-shelf NK cell therapy that is currently being studied in a Phase 1/2 trial with rituximab in patients with non-Hodgkin’s lymphoma (NHL). We are also developing AB-201 and AB-202, our first two chimeric antigen receptor-NK (CAR-NK) product candidates, for which we plan to file INDs in 2022. We are leveraging our proprietary platform and manufacturing capabilities to generate a broad pipeline of off-the-shelf NK cell therapeutic candidates for the treatment of hematologic malignancies and solid tumors.
Lead Underwriter
Cowen and Company, LLC, Evercore Group L.L.C, Goldman Sachs & Co. LLC
